Free Trial
OTCMKTS:NWBO

Northwest Biotherapeutics 11/9/2023 Earnings Report

Northwest Biotherapeutics logo
$0.36 +0.07 (+23.42%)
As of 04/23/2025 03:59 PM Eastern

Northwest Biotherapeutics EPS Results

Actual EPS
-$0.02
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Northwest Biotherapeutics Revenue Results

Actual Revenue
$0.41 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Northwest Biotherapeutics Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Northwest Biotherapeutics' next earnings date is estimated for Thursday, May 8, 2025, based on past reporting schedules.

Conference Call Resources

Northwest Biotherapeutics Earnings Headlines

What President Trump’s Executive Order 14154 means for your money
Nearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a former hedge fund manager who predicted the dotcom crash, the housing crisis, and the 2022 tech stock bloodbath - a little-known executive order from the President's first day in office could spark a paradigm-shift that will likely catch millions of Americans off guard.
See More Selective Insurance Group Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Northwest Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Northwest Biotherapeutics and other key companies, straight to your email.

About Northwest Biotherapeutics

Northwest Biotherapeutics (OTCMKTS:NWBO), a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.

View Northwest Biotherapeutics Profile

More Earnings Resources from MarketBeat